<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655248</url>
  </required_header>
  <id_info>
    <org_study_id>S2410</org_study_id>
    <nct_id>NCT04655248</nct_id>
  </id_info>
  <brief_title>ACURATE neo2™ Post Market Clinical Follow up Study</brief_title>
  <official_title>ACURATE neo2™ Post Market Clinical Follow up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ACURATE Neo2 PMCF is aimed at collecting clinical and device performance outcomes data&#xD;
      with the ACURATE neo2™ Transfemoral Aortic Valve System as used in routine clinical practice&#xD;
      for the treatment of severe calcific aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ACURATE neo2 PMCF is a prospective, open-label, single-arm, multicenter, observational&#xD;
      post-market surveillance study. All subjects deemed treatable with the ACURATE neo2 valve&#xD;
      will be approached to participate in the study.&#xD;
&#xD;
      A subject who provides an Informed Consent Form (ICF) approved by the Independent Ethics&#xD;
      Committee (IEC) and signed by the subject or the subject's legally authorized representative&#xD;
      is considered enrolled once an attempt is made to insert the commercially available ACURATE&#xD;
      neo2 Transfemoral Delivery System. Approximately 200 subjects will be enrolled.&#xD;
&#xD;
      Follow-up will occur at pre-discharge, 30 days, 1 year, and then annually from 2 through 5&#xD;
      years post index procedure per standard of care. Visits are in-person through 1 year and&#xD;
      in-person (preferred) or via telephone interview in years 2 through 5. All subjects will&#xD;
      undergo 4D computed tomography (CT) imaging at 30 days and 1 year.&#xD;
&#xD;
      ACURATE neo2 PMCF Study Design Overview Abbreviations: CT=computed tomography; ICF=Informed&#xD;
      Consent Form&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint:</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality after the index implant procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Imaging Endpoint:</measure>
    <time_frame>30 days</time_frame>
    <description>Hypoattenuated leaflet thickening (HALT) as measured by 4D CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints adjudicated by an independent Clinical Events Committee</measure>
    <time_frame>all 5 years</time_frame>
    <description>All-cause mortality (cardiovascular and non-cardiovascular) Stroke (disabling and non-disabling) Bleeding (life-threatening [or disabling] and major) Vascular complications (major) Hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Safety Endpoints</measure>
    <time_frame>all 5 years</time_frame>
    <description>Myocardial infarction (periprocedural [≤72 hours post index procedure] and spontaneous [&gt;72 hours post index procedure])&#xD;
Acute kidney injury (≤7 days post index procedure) based on the AKIN System Stage 3 (including renal replacement therapy) and Stage 2&#xD;
Repeat procedure for valve-related dysfunction (surgical or interventional therapy)&#xD;
New permanent pacemaker implantation resulting from new or worsened conduction disturbances&#xD;
New onset of atrial fibrillation or atrial flutter&#xD;
Coronary obstruction (≤3 days post index procedure)&#xD;
Ventricular septal perforation (≤3 days post index procedure)&#xD;
Annular rupture (≤3 days post index procedure)&#xD;
Cardiac tamponade (≤3 days post index procedure)&#xD;
Valve migration&#xD;
Valve embolization&#xD;
Ectopic valve deployment&#xD;
Transcatheter aortic valve (TAV)-in-TAV deployment&#xD;
Prosthetic aortic valve thrombosis&#xD;
Prosthetic aortic valve endocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic Aortic Valve Performance as measured by transthoracic echocardiography (TTE)</measure>
    <time_frame>Discharge, 30 days, annualty from year 1 to 5</time_frame>
    <description>Effective orifice area (EOA), Mean and Peak aortic gradients, peak aortic velocity, and grade of aortic regurgitation/paravalvular leak (PVL).&#xD;
Center-reported TTE measures will also be collected annually at 2 through 5 years per local standard of care for TAVI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL Quality of Life questionnaire (EQ-5D-5L)</measure>
    <time_frame>Baseline, 30-day, 1-year</time_frame>
    <description>Health status as evaluated by the EQ-5D-5L Quality Of Life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional classification</measure>
    <time_frame>Baseline, Discharge, 30 days, annualty from year 1 to 5</time_frame>
    <description>Classification of heart failure symptoms as evaluated by NYHA classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessments using 4D CT-scan</measure>
    <time_frame>30 days 1 year</time_frame>
    <description>Assessment of leaflet mobility&#xD;
Assessment of hypoattenuated leaflet thickening (HALT)&#xD;
Assessment of leaflet thrombosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Calcification</condition>
  <condition>Aortic Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation/Replacement</intervention_name>
    <description>The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic heart disease due to severe native calcific aortic stenosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        There are no specific inclusion criteria set for this post-market surveillance study. A&#xD;
        subject must sign an IEC/REB-approved ICF and the ACURATE neo2 Transfemoral Aortic Valve&#xD;
        System should be used according to the commercial IFU.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        EC1.Subject has a previous bioprosthesis in the aortic position.&#xD;
&#xD;
        EC2. Subject has eGFR &lt;30 mL/min (chronic kidney disease stage IV or stage V).&#xD;
&#xD;
        EC3. Subject has atrial fibrillation that cannot be rate controlled to ventricular response&#xD;
        rate &lt; 60 bpm.&#xD;
&#xD;
        EC4. Subject is expected to undergo chronic anticoagulation therapy after the TAVI&#xD;
        procedure&#xD;
&#xD;
        Note : Subjects treated with short-term anticoagulation post-procedure can be included; in&#xD;
        these subjects the 30-day imaging will be performed 30 days after discontinuation of&#xD;
        anticoagulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Søndergaard, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won-Keun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Nozza</last_name>
    <phone>+3902269831</phone>
    <email>michele.nozza@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bryn Jones</last_name>
    <email>bryn.jones@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian J Terkelsen, Prof.</last_name>
      <phone>+45 89496168</phone>
      <email>christian_juhl_terkelsen@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Søndergaard, Prof.</last_name>
      <phone>+45 35458693</phone>
      <email>lars.soendergaard.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Nissen, MD PhD</last_name>
      <phone>+45 66 11 33 33</phone>
      <email>Henrik.Nissen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH Herz und Thorax Zentrum Abteilung Kardiologie/Kardiochirurgie</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-Keun Kim, MD</last_name>
      <phone>+49 6032 996 6152</phone>
      <email>w.kim@kerckhoff-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HDZ Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Rudolph, Prof.</last_name>
      <email>tanja.rudolph@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Möllmann, Prof.</last_name>
      <phone>+49 6032 9960</phone>
      <email>helge.moellmann@joho-dortmund.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Wolf</last_name>
    </contact>
    <contact_backup>
      <email>A.Wolf@contilia.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hilker, Prof.</last_name>
      <phone>+49 941 944 19805</phone>
      <email>michael.hilker@klinik.uni-regensburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U Policlinico &quot;G.Rodolico - San Marco&quot;</name>
      <address>
        <city>Catania</city>
        <state>CA</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Tamburino, Prof.</last_name>
      <phone>+39 0957436201</phone>
      <email>tambucor@unict.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Montorfano, MD</last_name>
      <phone>+39 02 26437331</phone>
      <email>montorfano.matteo@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sonia Petronio, Prof.</last_name>
      <phone>+39 050 995313</phone>
      <email>as.petronio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Van Mieghem, Prof.</last_name>
      <phone>+31 10 7035260</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Stella, MD PhD</last_name>
      <phone>+31 302509433</phone>
      <email>P.stella@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramiro Trillo, M.D.</last_name>
      <phone>+34 981 950 789</phone>
      <email>ramirotrillo@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio J. Amat-Santos, M.D.</last_name>
      <phone>+34657923040</phone>
      <email>ijamat@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University, Cardiology department</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Götberg, MD PhD</last_name>
      <phone>+46 46 17 76 77</phone>
      <email>matthias.gotberg@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Rück, MD PhD</last_name>
      <phone>+46 707 787742</phone>
      <email>andreas.ruck@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Kasel, MD</last_name>
      <email>kasel@dhm.mhn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Appleby, MD</last_name>
      <phone>+441516003104</phone>
      <email>Clare.Appleby@lhch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Kharbanda, Prof.</last_name>
      <phone>+44 (0) 01865 223349</phone>
      <email>rajesh.kharbanda@orh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy. (http://www.bostonscientific.com/en-US/data-sharing-requests.html)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

